Tema Obesity & Cardiometabolic ETF (HRTS)
After hours:
| Previous close | 30.90 |
| Open | 30.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 30.70 - 30.95 |
| 52-week range | 26.26 - 35.58 |
| Volume | |
| Avg. volume | 26,831 |
| Net assets | 59.53M |
| NAV | 30.86 |
| PE ratio (TTM) | N/A |
| Yield | N/A |
| YTD daily total return | 0.95% |
| Beta (5Y monthly) | 0.00 |
| Expense ratio (net) | 0.75% |
| Inception date | 2023-11-20 |
- Yahoo Finance Video
'Continued innovation' is key when investing in weight loss trend
GLP-1 weight-loss drugs' popularity has paved the way for broadening use cases for people seeking a healthier lifestyle; the Food and Drug Administration (FDA) approved Novo Nordisk's (NVO) Wegouvy to use in treating and decreasing overweight patients' elevated cardiac risks. Tema ETFs Chief Investment Officer Yuri Khodjamirian highlights the pharmaceutical trend's ability to mainstream weight-loss treatments and ways to invest in the healthcare space. Khodjamirian's firm manages its own Tema Cardiovascular and Metabolic ETF (HRTS) "It is extremely important that you're selective. The first thing, you need to have a precise exposure of the theme. you want to make sure the companies that are under the hood in the ETFs are the companies that are going to be winning the way forward in terms of forward-looking winners rather than backward-looking winners," Khodjamirian says. "A lot of times you see in ETFs you have the historic winners rather than future ones." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
